Antipsychotic Medication Classification and Treatment

Introduction to Antipsychotic Classification

The American Psychiatric Association notes that antipsychotics are traditionally classified into first-generation (typical), second-generation (atypical), and third-generation agents, though this classification system is increasingly recognized as clinically misleading and should not guide treatment selection 1, 2

High-potency first-generation antipsychotic agents, such as haloperidol, are less sedating but cause more extrapyramidal symptoms, according to the American Academy of Pediatrics 3, 4
Low-potency first-generation antipsychotic agents, such as chlorpromazine, are more sedating with fewer extrapyramidal symptoms but greater anticholinergic, antihistaminic, and alpha-adrenergic effects, as reported by the American Academy of Pediatrics 3, 5
Second-generation antipsychotics, such as amisulpride and olanzapine, act as serotonin-dopamine receptor antagonists, offering different side effect profiles, as noted by the American Academy of Pediatrics and the National Institute of Mental Health 3, 4
Third-generation antipsychotics, such as aripiprazole, have partial dopamine receptor agonist activity, distinguishing them pharmacologically, according to the American Academy of Pediatrics 3, 4

The distinction between first-generation and second-generation antipsychotics is not a distinct category from either a pharmacological or clinical perspective and should not be used to guide psychotropic choice, as stated by the American Psychiatric Association and the National Institute of Mental Health 1, 2
Both typical and atypical antipsychotics carry similarly increased risks of sudden cardiac death, with dose-dependent effects, as reported by the European Society of Cardiology 6
Treatment selection should be based on individual drug pharmacodynamic profiles, side-effect profiles, and patient-specific factors rather than generational classification, according to the American Psychiatric Association and the National Institute of Mental Health 1, 2

When selecting antipsychotics, switch to compounds with different pharmacodynamic profiles rather than relying on generational categories, as recommended by the American Psychiatric Association and the National Institute of Mental Health 1, 2
Do not assume atypical antipsychotics are universally safer—both classes carry cardiac risks and require monitoring, as noted by the European Society of Cardiology 6, 7